Episode 2: Building on Amyloid Lowering: Key Insights from Recent Data and Prospects for Complementary Therapeutic Approaches

Featuring:
Anthony Caggiano, M.D., Ph.D.
Cognition Therapeutics
Chief Medical Officer and Head of R&D
Christopher H. van Dyck, M.D.
Yale University School of Medicine
Professor of Psychiatry, Neurology, and Neuroscience; Director of the Division of Aging and Geriatric Psychiatry; Director of the Alzheimer’s Disease Research Center
Anton P. Porsteinsson, M.D.
University of Rochester School of Medicine and Dentistry
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine; and Director of the Alzheimer’s Disease Care, Research and Education Program (AD-CARE)
Index:
0:00 Introduction
1:47 Reactions to lecanemab results
3:48 Impact of targeting plaque
6:46 Potentially complementary strategies
11:24 Future of Alzheimer’s therapies
13:40 Conclusion

share this video

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.